De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Zevra Therapeutics Beheer
Beheer criteriumcontroles 0/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Neil McFarlane
Algemeen directeur
US$3.4m
Totale compensatie
| Percentage CEO-salaris | 4.6% |
| Dienstverband CEO | less than a year |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 1.8yrs |
| Gemiddelde ambtstermijn bestuur | 1.5yrs |
Recente managementupdates
Recent updates
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18KemPharm reports orange book listing for six U.S. patents covering serdexmethylphenidate
May 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensatie versus markt: De totale vergoeding ($USD 3.45M ) Neil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).
Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Neil te vergelijken met de prestaties van het bedrijf.
CEO
Neil McFarlane (51 yo)
less than a year
Tenure
US$3,445,231
Compensatie
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He has served as Director at Collegi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | less than a year | US$3.45m | geen gegevens | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.052% $ 186.4k | |
| CFO, Secretary & Treasurer | 9.3yrs | US$2.26m | 0.035% $ 126.5k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.8yrs | US$1.82m | 0.0066% $ 24.0k | |
| Chief Scientific Officer | 1.8yrs | US$1.08m | 0.0052% $ 18.8k | |
| Vice President of Investor Relations & Corporate Communications | 2.2yrs | geen gegevens | geen gegevens | |
| Chief Legal Officer | less than a year | geen gegevens | geen gegevens | |
| Chief People Officer | less than a year | geen gegevens | geen gegevens | |
| Senior Vice President of Manufacturing | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Clinical Development | 1.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Medical Affairs & Advocacy | 1.8yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | less than a year | geen gegevens | geen gegevens |
1.8yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ZVRA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | less than a year | US$3.45m | geen gegevens | |
| Independent Director | 1.5yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 3.2yrs | US$324.39k | 0.0014% $ 4.9k | |
| Member of Scientific and Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 1.5yrs | US$264.31k | 0.057% $ 205.5k | |
| Independent Director | 1.5yrs | US$260.67k | 0.0019% $ 6.8k | |
| Chairman of Scientific and Medical Advisory Board | 17.8yrs | geen gegevens | geen gegevens | |
| Member of Scientific & Medical Advisory Board | no data | geen gegevens | geen gegevens | |
| Co-Chair of Physician Advisory Council | 11yrs | geen gegevens | geen gegevens | |
| Co-Chair of Physician Advisory Council | 11yrs | geen gegevens | geen gegevens | |
| Independent Director | 1.2yrs | US$243.04k | 0.038% $ 137.0k |
1.5yrs
Gemiddelde duur
58yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ZVRA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw bestuur.